Key Points
- Director Thomas Carey bought 75,000 shares at an average price of $0.63, a $47,250 investment that increased his holdings by 21.77% to 419,456 shares.
- Standard BioTools reported quarterly EPS of $0.03, beating the consensus estimate of a $0.02 loss, and revenue of $19.39 million versus $18.80 million expected.
- The shares opened at $0.62, near their one-year low of $0.59; analysts’ average rating is “Reduce,” with one Hold and one Sell rating.
Standard BioTools Inc. (NASDAQ:LAB - Get Free Report) Director Thomas Carey acquired 75,000 shares of the stock in a transaction dated Thursday, November 5th. The stock was bought at an average cost of $0.63 per share, with a total value of $47,250.00. Following the completion of the purchase, the director directly owned 419,456 shares in the company, valued at approximately $264,257.28. The trade was a 21.77% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.
Standard BioTools Stock Performance
Shares of Standard BioTools stock opened at $0.62 on Friday. The stock has a market cap of $245.12 million, a price-to-earnings ratio of 2.82 and a beta of 1.52. The stock has a 50 day moving average price of $0.68 and a 200-day moving average price of $0.90. Standard BioTools Inc. has a one year low of $0.59 and a one year high of $1.72.
Standard BioTools (NASDAQ:LAB - Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.05. The company had revenue of $19.39 million for the quarter, compared to analyst estimates of $18.80 million. Standard BioTools had a negative return on equity of 5.61% and a net margin of 157.62%.
Institutional Trading of Standard BioTools
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LAB. BlackRock Inc. bought a new stake in Standard BioTools in the second quarter worth about $6,791,000. Sone Capital Management LLC purchased a new position in shares of Standard BioTools during the second quarter valued at approximately $1,755,000. GSA Capital Partners LLP bought a new position in shares of Standard BioTools during the second quarter valued at approximately $977,000. Man Group plc bought a new position in shares of Standard BioTools during the second quarter valued at approximately $611,000. Finally, Staley Capital Advisers Inc. purchased a new stake in shares of Standard BioTools in the first quarter worth approximately $581,000. 53.74% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reiterated a "sell (d)" rating on shares of Standard BioTools in a research report on Wednesday. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Standard BioTools currently has an average rating of "Reduce".
Read Our Latest Research Report on Standard BioTools
Standard BioTools Company Profile
(
Get Free Report)
Standard BioTools Inc (NASDAQ: LAB) develops and supplies technologies, instruments and consumables used by researchers and biopharmaceutical companies to analyze biological systems. Its portfolio supports applications in proteomics, genomics, single-cell analysis, mass cytometry and spatial biology.
The company's offerings include the SomaScan protein profiling platform, which measures large numbers of proteins from biological samples, as well as CyTOF mass cytometry systems for high-dimensional single-cell analysis.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
